Dr. Daniel T. Chang

Dr. Daniel Chang is a nationally and internationally recognized expert in radiotherapy for GI malignancies. His primary research interest is in advanced radiotherapy techniques, primarily with stereotactic body radiotherapy (SBRT). He has led several studies investigating and establishing the efficacy and safety for SBRT for these diseases for liver and pancreatic tumors. His other research interests include normal tissue tolerances, quality of life after radiotherapy, and combining radiotherapy with targeted agents. In addition, he has a strong interest in the use of radiotherapy, particularly in combination with systemic agents, in patients with metastatic disease. Another area of interest is in health care utilization for patients with metastatic disease and using machine learning and other approaches to optimize care during the end-of-life period.Dr. Chang is interested in developing novel modalities and technologies for delivering radiotherapy. He previously led the FDA trial that led to approval of PET-guided radiotherapy, which in broader terms, is called Biology-guided radiotherapy. In addition, he has experience with MR-guided radiotherapy, and he is interested in exploring the role of particle therapy and heave ion radiotherapy.Dr. Chang received his MD from Wayne State University in 2002 and completed his residency in Radiation Oncology at the University of Florida in Gainesville, Florida in 2007. He then joined the Department of Radiation Oncology at Stanford University from 2007-2022, having previously served as residency program director from 2012-2017 and the Vice Chair of Clinical Operations from 2017-2022 where he was also the Sue and Bob McCollum Professor in Radiation Oncology.Dr. Chang is a member of the American Society of Radiation Oncology (ASTRO), American Radium Society (ARS), and the American Society of Clinical Oncology (ASCO). He serves on the scientific committee for ASTRO, ASCO, and GI ASCO. He has authored or co-authored over 190 peer-reviewed publications for journals including Journal of Clinical Oncology, Journal of the National Cancer Institute, Clinical Cancer Research, Radiology, International Journal of Radiation Oncology, Biology, and Physics, Radiotherapy and Oncology, and Cancer. He served as the senior editor for the GI section of the International Journal of Radiation Oncology, Biology, and Physics from 2013-2017 and is currently on the editorial board for Practical Radiation Oncologysince 2020. He served on the Hepatobiliary Panel for the National Cancer Comprehensive Network (NCCN) guidelines from 2013-2022, helping to shape national guidelines for the work-up, diagnosis, and treatment of patients with hepatobiliary cancers. He is currently the track chair for the GI track for the ASTRO Annual Meeting Scientific Committee. He also serves on the Education Committee for the Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary Track for the ASCO annual meeting starting in 2023.

Dr. Chang is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Anal Cancer, Squamous Cell Carcinoma of the Anal Canal (SCAC), Pancreaticoduodenectomy, and Pancreatectomy.

Dr. Chang is board certified in Radiation Oncology. He is actively involved in clinical research, co-authoring 247 peer reviewed articles and participating in 6 clinical trials. Dr. Chang is currently accepting new patients.